Skip to main
  1. Stocks
  2. Revolution Medicines
  3. Forecast
RVMD

Revolution Medicines (RVMD) Stock Forecast & Price Target

Revolution Medicines (RVMD) Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 48%
Buy 48%
Hold 4%
Sell 0%
Strong Sell 0%

Bulls say

Revolution Medicines is viewed positively because RASONQUE’s first commercial quarter delivered about $198M in sales in 3Q26, far above both the ~$14M estimate and the $24.9M consensus, while treatment reached over 5,000 unique PDAC patients shortly after the August 26 FDA approval. The company’s strong cash position of roughly $3.72B, narrower 3Q26 net loss of $1.90 per share versus the expected $2.42, and R&D and SG&A that remained broadly manageable support financial durability and a runway into profitability. Its outlook is further strengthened by a differentiated RAS platform with broad pipeline optionality across PDAC, NSCLC, and CRC, including ongoing or planned late-stage trials and a pan-RAS mechanism that may support broad adoption and future growth.

Bears say

Revolution Medicines is viewed negatively because its valuation depends heavily on a small number of clinical-stage pipeline programs, leaving the company exposed to binary development risk. Setbacks in those programs, a regulatory review that takes longer than expected, or more modest commercial uptake could materially weaken the investment case and pressure the company’s long-term fundamentals. The downside scenario underscores that even if the science remains promising, delayed approval or softer adoption could limit value creation and keep shares vulnerable to substantial downside.

Revolution Medicines (RVMD) has been analyzed by 23 analysts, with a consensus rating of Buy. 48% of analysts recommend a Strong Buy, 48% recommend Buy, 4% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Revolution Medicines and is not a guaranteed prediction by Public.com or investment advice.

Revolution Medicines (RVMD) Analyst Forecast & Price Prediction

Get the latest Revolution Medicines (RVMD) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Revolution Medicines (RVMD)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Revolution Medicines (RVMD) Forecast

Analysts have given Revolution Medicines (RVMD) a Buy based on their latest research and market trends.

According to 23 analysts, Revolution Medicines (RVMD) has a Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $238.39, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $238.39, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Revolution Medicines (RVMD)


Revolution Medicines (RVMD) Analyst Forecast & Price Prediction

Get the latest Revolution Medicines (RVMD) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Revolution Medicines (RVMD)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover RVMD stock data and trends